Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section
Descripción del Articulo
Background: Postpartum haemorrhage (PPH) is the single most important cause of maternal mortality, and uterine atony is its most common cause. The best treatment is prevention. Oxytocin reduces the risk of PPH. In Spain carbetocin has been marketed, a human oxytocin analogue that has rapid onset of...
Autores: | , , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2014 |
Institución: | Sociedad Peruana de Obstetricia y Ginecología |
Repositorio: | Revista Peruana de Ginecología y Obstetricia |
Lenguaje: | español |
OAI Identifier: | oai:ojs.pkp.sfu.ca:article/110 |
Enlace del recurso: | http://51.222.106.123/index.php/RPGO/article/view/110 |
Nivel de acceso: | acceso abierto |
id |
REVSPOG_e45863ad4e0a95c5508111fdb2145dd7 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/110 |
network_acronym_str |
REVSPOG |
network_name_str |
Revista Peruana de Ginecología y Obstetricia |
repository_id_str |
. |
dc.title.none.fl_str_mv |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section Oxitocina frente a carbetocina para prevenir hemorragias posparto tras cesárea |
title |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
spellingShingle |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section Navarro Díaz, Begoña |
title_short |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
title_full |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
title_fullStr |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
title_full_unstemmed |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
title_sort |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean section |
dc.creator.none.fl_str_mv |
Navarro Díaz, Begoña Castro Samper, Noelia Córdoba Medina, Nerea Fernández Díaz, Laura Millà Jover, Alfredo Rodríguez Ingelmo, José María |
author |
Navarro Díaz, Begoña |
author_facet |
Navarro Díaz, Begoña Castro Samper, Noelia Córdoba Medina, Nerea Fernández Díaz, Laura Millà Jover, Alfredo Rodríguez Ingelmo, José María |
author_role |
author |
author2 |
Castro Samper, Noelia Córdoba Medina, Nerea Fernández Díaz, Laura Millà Jover, Alfredo Rodríguez Ingelmo, José María |
author2_role |
author author author author author |
description |
Background: Postpartum haemorrhage (PPH) is the single most important cause of maternal mortality, and uterine atony is its most common cause. The best treatment is prevention. Oxytocin reduces the risk of PPH. In Spain carbetocin has been marketed, a human oxytocin analogue that has rapid onset of action and an average life 4-10 times longer than oxytocin, producing tonic contraction that reduces postpartum blood loss. Objectives: To compare effects of carbetocin and oxytocin, in order to prevent postpartum haemorrhage after cesarean section. Design: Observational retrospective comparative study. Setting: Obstetrics and Gynecology Service, Hospital General Universitario de Elche, Alicante, España. Participants: Pregnant women with risk factor of uterine atony following cesarean section. Methods: From April 2010 through March 2012 247 women with a risk factor for uterine atony after cesarean section The effects of administering 100 micrograms of carbetocin and 10 UI of oxytocin following delivery were compared. Hemoglobin levels prior and 24-48 hours after cesarean section and the percentage of transfusions given were assessed. Main outcome measures: Anemia, blood transfusions, intravenous iron. Results: In the group of carbetocin, hemoglobin decreased less than in the oxytocin group (P=0.56), and there was less anaemia after cesarean section (P=0,852). Transfusions and intravenous iron did not provide conclusive data. Conclusions: There were no significant differences between carbetocin and oxytocin to prevent PPH after cesarean sections. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-05-21 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://51.222.106.123/index.php/RPGO/article/view/110 |
url |
http://51.222.106.123/index.php/RPGO/article/view/110 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
http://51.222.106.123/index.php/RPGO/article/view/110/100 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
dc.source.none.fl_str_mv |
The Peruvian Journal of Gynecology and Obstetrics ; Vol. 60 No. 1 (2014); 53-58 Revista Peruana de Ginecología y Obstetricia; Vol. 60 Núm. 1 (2014); 53-58 2304-5132 2304-5124 reponame:Revista Peruana de Ginecología y Obstetricia instname:Sociedad Peruana de Obstetricia y Ginecología instacron:SPOG |
instname_str |
Sociedad Peruana de Obstetricia y Ginecología |
instacron_str |
SPOG |
institution |
SPOG |
reponame_str |
Revista Peruana de Ginecología y Obstetricia |
collection |
Revista Peruana de Ginecología y Obstetricia |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1845882445991247872 |
spelling |
Oxytocin versus carbetocine to prevent post partum hemorrhage following cesarean sectionOxitocina frente a carbetocina para prevenir hemorragias posparto tras cesáreaNavarro Díaz, BegoñaCastro Samper, NoeliaCórdoba Medina, NereaFernández Díaz, LauraMillà Jover, AlfredoRodríguez Ingelmo, José MaríaBackground: Postpartum haemorrhage (PPH) is the single most important cause of maternal mortality, and uterine atony is its most common cause. The best treatment is prevention. Oxytocin reduces the risk of PPH. In Spain carbetocin has been marketed, a human oxytocin analogue that has rapid onset of action and an average life 4-10 times longer than oxytocin, producing tonic contraction that reduces postpartum blood loss. Objectives: To compare effects of carbetocin and oxytocin, in order to prevent postpartum haemorrhage after cesarean section. Design: Observational retrospective comparative study. Setting: Obstetrics and Gynecology Service, Hospital General Universitario de Elche, Alicante, España. Participants: Pregnant women with risk factor of uterine atony following cesarean section. Methods: From April 2010 through March 2012 247 women with a risk factor for uterine atony after cesarean section The effects of administering 100 micrograms of carbetocin and 10 UI of oxytocin following delivery were compared. Hemoglobin levels prior and 24-48 hours after cesarean section and the percentage of transfusions given were assessed. Main outcome measures: Anemia, blood transfusions, intravenous iron. Results: In the group of carbetocin, hemoglobin decreased less than in the oxytocin group (P=0.56), and there was less anaemia after cesarean section (P=0,852). Transfusions and intravenous iron did not provide conclusive data. Conclusions: There were no significant differences between carbetocin and oxytocin to prevent PPH after cesarean sections.Antecedentes: La hemorragia posparto (HPP) es la causa aislada más importante de mortalidad materna y su causa más frecuente es la atonía uterina. El mejor tratamiento es su prevención. La oxitocina reduce el riesgo de HPP. Se ha comercializado en España la carbetocina, análogo de la oxitocina humana que tiene inicio de acción rápido y una vida media 4 a 10 veces más larga que la oxitocina, produciendo una contracción tónica que reduce la pérdida hemática posparto. Objetivos: Comparar efectos de carbetocina y oxitocina para prevenir hemorragias posparto tras cesárea. Diseño: Estudio observacional retrospective de comparación. Institución: Servicio de Obstetricia y Ginecología, Hospital General Universitario de Elche, Alicante, España. Participantes: Gestantes con factor de riesgo de atonía uterina tras cesárea. Metodología: Se ha incluido 247 mujeres con algún factor de riesgo de atonía uterina tras cesárea, estudiadas desde abril de 2010 hasta marzo de 2012. Se ha comparado los efectos de administrar 100 microgramos de carbetocina y 10 UI de oxitocina tras el alumbramiento. Se ha evaluado las cifras de hemoglobina previas a la cesárea y tras 24 a 48 horas de la misma, y el porcentaje de transfusiones realizadas. Principales medidas de resultados: Anemia, transfusiones sanguíneas, hierro intravenoso. Resultados: En el grupo carbetocina, la hemoglobina tras la cesárea descendió menos (P=0,56) y existió menos casos de anemia tras la misma (P=0,852). Las transfusiones y el hierro intravenoso no aportaron datos concluyentes. Conclusiones: No existieron diferencias estadísticamente significativas entre carbetocina y oxitocina para prevenir HPP tras cesáreas.Sociedad Peruana de Obstetricia y Ginecología2014-05-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://51.222.106.123/index.php/RPGO/article/view/110The Peruvian Journal of Gynecology and Obstetrics ; Vol. 60 No. 1 (2014); 53-58Revista Peruana de Ginecología y Obstetricia; Vol. 60 Núm. 1 (2014); 53-582304-51322304-5124reponame:Revista Peruana de Ginecología y Obstetriciainstname:Sociedad Peruana de Obstetricia y Ginecologíainstacron:SPOGspahttp://51.222.106.123/index.php/RPGO/article/view/110/100info:eu-repo/semantics/openAccessoai:ojs.pkp.sfu.ca:article/1102014-05-21T09:23:42Z |
score |
13.361153 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).